Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel

Clinical Cancer Research

Volumn 2, Issue 3, 1996, Pages 549-552

  Obasaju, Coleman K ^a   Johnson, Steven W ^a   Rogatko, Andre ^a   Kilpatrick, Debbie ^a   Brennan, James M ^a   Hamilton, Thomas C ^a   Ozols, Robert F ^a   O'Dwyer, Peter J ^a   Gallo, James M ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG INTERACTION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARBOPLATIN; DRUG INTERACTIONS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL;

EID: 0029926645     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Rowinsky, E. K., and Donehower, R. C. Paclitaxel (Taxol). N. Engl. J. Med. 332: 1004-1012, 1995.
2. McGuire, W. P., Rowinsky, E. K , Rosenshein, N. B., Grumbine, F. C., Ettinger, D. S., Armstrong, D. K., and Donehower, R. C. Taxol, a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Intern Med., 111: 273-279, 1989.
3. Thigpen, T , Blessing, J., Bail, H., Hummel, S., and Barret, R. Phase II trial of Taxol as second-line therapy for ovarian cancer: a gynecologic oncology group study. Proc. Am. Soc. Clin Oncol., 9: 156, 1990.
4. Holmes, F. A., Walters, R. S., Therigult, R. L., Forman, A. D., Newton, L. K., Rabner, M. N., Buzdar, A. U , Frye, D. K., and Hortobagyi, G. N. Phase II trial of Taxol. An active drug in metastatic breast cancer. J. Natl. Cancer Inst., 83: 1797-1805, 1991.
5. Murphy, W. K., Winn, R. S , Fossella, R. F., Shin, D. M., Hynes, H. E., Gross, H. M., Davila, E., Leimert, J T., Dhingra, H. M., Raber, M. N., Krakoff, I. H., and Hong, W. K. A Phase II study of Taxol in patients with non-small cell lung cancer. Proc Am. Soc. Clin. Oncol., 11: 294, 1991.
6. Chang, A., Kim, K., Glick, J., Anderson, T., Karp., D., and Johnson, D. Phase II study of Taxol in patients with stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group (ECOG) results. Proc. Am. Soc. Clin. Oncol., 11: 293, 1992.
7. Rowinsky, E. K., Cazenave, L. A., and Donehower, R. C. A novel investigational antimicrotubule agent. J. Natl. Cancer Inst., 82: 1247-1259, 1990.
8. William, C. R. Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies. Monogr. J. Natl. Cancer Inst., 15: 47-53, 1993.
9. Clark, J. W., Santos-Moore, A. S., and Choy, H. Sequencing of Taxol and carboplatinum therapy. Proc. Am. Assoc. Cancer Res., 36: 298, 1995.
10. Rowinsky, E. K., Gilbert, M. R., McGuire, W. P., Noe, D. A., Grochow, L. B., Forastiere, A. A , Ettinger, D. S., Lubejko, B. G., and Clark, B. Sequences of Taxol and cisplatin: a phase I and pharmacologic study. J. Clin. Oncol., 9: 1692-1703, 1991.
11. McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Look, K. Y., Partridge, E. E., and Davidson, M. A phase II trial comparing cisplatin/cytoxan (PC) and cisplatin/Taxol (PT) in advanced ovarian cancer (AOC). Proc. Am. Soc. Clin. Oncol., 12: 255, 1993.
12. Calvert, A. H., Newell, D R., Gumbrell, L. A., O'Reilly, S., Burnell, M., Boxall, F. E., Siddik, Z. H., Judson, I. R., Gore, M. E., and Wiltshaw, E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol., 7: 1748-1756, 1989.
13. Cockcroft, D. W., and Gault, M. H. Prediction of creatinine clearance from serum creatinine. Nephron, 16: 31-41, 1976.
14. Schilder, R. J., LaCreta, F. P., Perez, R. P., Johnson, S. W., Brennan, J. M., Rogatko, A., Nash, S., McAleer, C., Hamilton, T. C., Roby, D., Young, R. C. Ozols, R. F., and O'Dwyer, P. J. Phase I and pharmacokinetic study of ormaplatin administered on a day 1 and day 8 schedule. Cancer Res., 54, 709-717, 1994.
15. 2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer. Cancer Chemother. Pharmacol., 33: 48-52, 1993.
16. Rocci, M. L., and Jusko, W. J. LAGRAN program for area and moments in pharmacokinetic analysis. Comput. Programs Biomed., 16: 203-216, 1983
17. Wagstaft, A. J , Ward, A., Benfield, P., and Heel, R. C Carboplatin. Drugs, 37: 162-190, 1989.
18. Rowinsky, E. K., Cazenave, L. A., and Donehower, R. C. Taxol: a novel investigational antimicrotubule agent. J. Natl. Cancer Inst., 82: 1247-1259, 1990.
19. Gianni, L. Use of Taxol with other anticancer agents Proceedings of the European Organization for Research on Treatment of Cancer Early Drag Development Meeting, p. 54. Corfu, Greece, 1995.
20. SOLO Power Analysis, J L. Hintze, BMDP Statistical Software, Los Angeles, CA. 1991
21. Gianni, L., Kearns, C. M., Giani, A., Capri, G., Vigano, L., Locatelli, A., Bonadonna, G , and Egorin, M. J. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J. Clin. Oncol , 13: 180-190, 1995.
22. Lam, F. C., Hung, C. T., and Perrier, D. Estimation of variance for harmonic mean half-lives. J. Pharm. Sci., 74: 229-231, 1985.